Effect of allopurinol on all-cause mortality in adults with incident gout: Propensity score-matched landmark analysis

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2145-2150

  Kuo, Chang Fu ^a,b   Grainge, Matthew J ^a   Mallen, Christian ^c   Zhang, Weiya ^a   Doherty, Michael ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

Allopurinol; Gout; Landmark analysis; Mortality; Propensity score

Indexed keywords

ALLOPURINOL;

ADULT; AGED; ARTICLE; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPENSITY SCORE; UNITED KINGDOM;

EID: 84983119876     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev246     Document Type: Article

References (20)

1. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9.
2. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
3. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 2014; Advance Access published 14 November 2014, doi: 10.1136/annrheumdis-2014-206410.
4. Kuo CF, Yu KH, See LC et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine 2011;78:577-80.
5. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 2014;312:2684-6.
6. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011;19:265-71.
7. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.
8. Doherty M, Jansen TL, Nuki G et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
9. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
10. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661-7.
11. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8.
12. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-71.
13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
14. Weiss GB, Bunce H III, Hokanson JA. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 1983;4:43-52.
15. Malek F, Ostadal P, Parenica J et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure- results of the Acute HEart FAilure Database registry. J Crit Care 2012;27: 737 e11-24.
16. Wu AH, Ghali JK, Neuberg GW et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010;160:928-33.
17. Luk AJ, Levin GP, Moore EE et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009;48:804-6.
18. Struthers AD, Donnan PT, Lindsay P et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34.
19. Dubreuil M, Zhu Y, Zhang Y et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2015;74:1368-72.
20. Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology 2010;49:105-11.